Diffusion Pharmaceuticals Inc.

BST:DP81 Stock Report

Market Cap: €12.5m

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Diffusion Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Key information

-19.2%

Earnings growth rate

48.6%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth raten/a
Return on equity-62.3%
Net Marginn/a
Last Earnings Update30 Sep 2022

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How Diffusion Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BST:DP81 Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 220-1587
30 Jun 220-2488
31 Mar 220-2488
31 Dec 210-2478
30 Sep 210-25710
30 Jun 210-17711
31 Mar 210-18711
31 Dec 200-1669
30 Sep 200-1669
30 Jun 200-1457
31 Mar 200-1256
31 Dec 190-1257
30 Sep 190-1456
30 Jun 190-1856
31 Mar 190-1866
31 Dec 180-2766
30 Sep 180-2066
30 Jun 180-1066
31 Mar 180466
31 Dec 170-365
30 Sep 170-765
30 Jun 170-1585
31 Mar 170-3065
31 Dec 160-1896
30 Sep 160-1896
30 Jun 160-1456

Quality Earnings: DP81 is currently unprofitable.

Growing Profit Margin: DP81 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: DP81 is unprofitable, and losses have increased over the past 5 years at a rate of 19.2% per year.

Accelerating Growth: Unable to compare DP81's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: DP81 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-15.9%).


Return on Equity

High ROE: DP81 has a negative Return on Equity (-62.32%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/02/13 22:24
End of Day Share Price 2022/11/16 00:00
Earnings2022/09/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Diffusion Pharmaceuticals Inc. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Swayampakula RamakanthH.C. Wainwright & Co.
David BautzZacks Investment Research Inc.
David BautzZacks Small-Cap Research